Potassium Acid Phosphate
- CAS Codes:7778-77-0
- PHARMGKB ID:7778-77-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: K-Phos Original.
Latin America
Argentina: Calcium Fluoricum Oligoplex; Brazil: Alitraq, Ensure, Glucerna, Jevity Plus, Neurotónico, Osmolite, Pediasure, Profort, Pulmocare.
Drug combinations
Chemistry
Potassium Acid Phosphate: H~2~PO~4~K. Mw: 136.08. Potassium phosphate, monobasic. CAS-7778-77-0.
Pharmacologic Category
Other Miscellaneous Therapeutic Agents. Urinary Acidifying Agent.
Mechanism of action
Principal intracellular cation, involved in transmission of nerve impulses, muscle contractions, enzyme activity, and glucose utilization.
Therapeutic use
Acidifies urine and lowers urinary calcium concentration. Reduces odor and rash caused by ammoniacal urine. Increases antibacterial activity of methenamine.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Severe renal impairment. Hyperkalemia, hyperphosphatemia. Infected magnesium ammonium phosphate stones.
Warnings and precautions
May cause genitourinary upset (e.g. abdominal pain, diarrhea, discomfort, nausea, vomiting) and lead to genitourinary ulceration, bleeding, perforation and/or obstruction. Severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (e.g. heart block, ventricular arrhythmias, asystole). Use with caution in renal impairment (contraindicated with severe impairment), in severe tissue breakdown (e.g. chemotherapy or hemodialysis), and in patients receiving concomitant medications or therapies which increase potassium (e.g. ACEI, potassium-sparing diuretics, potassium-containing salt substitutes).